Dubai: Dr. Ayman Al-Naeem, President of the Emirates Dermatology Society at the Emirates Medical Association and Chair of the 9th Emirates Dermatology Conference, announced the introduction of two new medications for the first time in the UAE, following their immediate approval by leading international regulatory authorities. Dr. Al-Naeem emphasized that the UAE has become a preferred destination for global drug manufacturers to launch their latest products annually due to its rapid pharmaceutical registration process.
According to Emirates News Agency, the first medication targets hidradenitis supportive, an inflammatory autoimmune disease with severe symptoms. This treatment is administered as an injection every 14 days on a lifelong basis to manage the symptoms. Dr. Al-Naeem explained that the second medication is aimed at treating bullous dermatoses, a chronic condition affecting predominantly older adults. This biological therapy is administered once every two weeks. Both treatments are covered by insur
ance companies in the UAE.
The 9th Dermatology Conference continued its sessions, focusing on the latest research and successful global experiences in treating complex dermatological diseases. Dr. Al-Naeem noted the use of artificial intelligence by dermatologists to aid in diagnosing skin conditions, which supports the provision of precise, effective treatments tailored to each patient’s needs.
The conference also highlighted advancements in dermatologic science, laser technologies, and aesthetic medicine. The goal is to enhance healthcare quality and equip participating physicians with advanced skills and knowledge, contributing to the highest standards of care for dermatology patients.